Exelixis’ Late-Stage Melanoma Combination Falls Short in Phase III Trial

, , , , , , , , , ,

Shares of Exelixis fell after the company disclosed in a U.S. SEC filing that a Phase III melanoma trial failed to hit endpoints.

Read more
/by